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In an attempt to investigate the eﬀects of treatment of human leishmaniasis, the cytokines produced by peripheral blood mononu-
clearcells(PBMCs)ofpatientswithcutaneousleishmaniasis(CL)andmucocutaneousleishmaniasis(MCL)undertreatmentwith
amphotericin B were determined during the active disease from cocultures of cells and Leishmania (Viannia) braziliensis antigens.
PBMC of these patients exhibited a nonsigniﬁcant marginal increased production of TNF-α upon antigen stimulation. However,
under the same antigenic stimulus, patients with active MCL presented higher IFN-γ production compared to patients with CL.
This increased IFN-γ production was accompanied by a drastically augmented IL-12 synthesis from cells of MCL patients. The
highlighted T cell responses could be relevant for sound control measures of protozoan infections with emphasis on the combined
usage of immunoenhancing agents and antiprotozoal drugs.
Copyright © 2007 Washington R. Cuna et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Leishmaniasisisavector-bornediseasecausedbyobligatein-
tramacrophage protozoan parasites of the genus Leishmania
[1, 2]. The infecting Leishmania species determines the clin-
ical presentation of disease, of which there are three dom-
inant clinical forms: cutaneous leishmaniasis (CL), muco-
cutaneous leishmaniasis (MCL), and visceral leishmaniasis
[1, 2]. In Bolivia, the etiological agent of both, CL and MCL
is Leishmania (Viannia) braziliensis, formerly known as the
L. braziliensis complex [3]. While CL is characterized by sin-
gle or multiple ulcerated dermal lesions, MCL which devel-
ops as a complication of L. (V.) braziliensis CL in 5%–20%
of patients [4] from parasite dissemination to the upper res-
piratory tract mucosa, involving the nasal, pharyngeal, and
laryngeal mucosa, leads to extensive tissue destruction [5, 6].
CL either heals spontaneously or promptly responds to an-
timonial therapy but MCL usually evolves chronically and is
diﬃcult to treat [7]. Then, amphotericin B (amB) is an alter-
native for patients who fail to respond to pentavalent anti-
monial therapy.
It has been known that amB potentiates the antimicro-
bial and tumoricidal activities of macrophages [8], either di-
rectly [9] or via induction of cytokines such as tumor necro-
sis factor-α (TNF-α) and interleukin-1β (IL-1β), as well as
generation of a respiratory burst [10, 11]. Apart from these
eﬀects, little is known about the mechanisms associated with
the eﬃcacy of this compound in the treatment of MCL.
Therefore, it was of interest to determine the participation
of other soluble factors, apart from TNF-α,i na m B - t r e a t e d
mucocutaneous leishmaniasis, keeping in mind that activa-
tion of the infected macrophages to kill intracellular para-
sites is carried out through a cell-mediated response that re-
quires the classic features of antigen presentation and pro-
duction of IL-12 by macrophages and activation of TH1l ym -
phocytes with production of interferon-γ (IFN-γ)t oa c t i -
vate the macrophages. The present study was aimed at elu-
cidating the participation of critical soluble factors associ-
ated with amB treatment that could alleviate, in future, the
collateral eﬀects of this arduous treatment by combining im-
munochemotherapy with lower doses of drug.
In the present investigation, we present evidence for an
exacerbated TH1 immune response in MCL treated with
amB, manifested by an elevated synthesis of IFN-γ which di-
rectly relates to a great increase in IL-12 production.
2. MATERIALS AND METHODS
Patients
Twenty four leishmaniasis patients were included in this
study, 12 with CL and 12 with MCL, including male and2 Journal of Biomedicine and Biotechnology
female, average age 30 years old. All of them acquired the
disease in the Yungas Valley of La Paz Department, an en-
d e m i ca r e af o rL( V . )b r a z i l i e n s i sinfection. Patients included
in the study presented clinical features compatible with CL
or MCL, were positive in both the Montenegro skin test and
the serology for L. (V.) braziliensis antibodies (indirect im-
munoﬂuorescence). At the moment of taking the blood sam-
ples, MCL patients were being treated with amphotericin B,
at a dose of 1mg/kg/day by infusion till a total dose of 1 to
3grams, and had received mean doses of 7.5 (5–10 doses).
CL patients were not receiving treatment when blood sam-
ples were taken. Informed consent was obtained from each
participating donor before taking blood samples.
Antigens
The parasite lysate (ALb) utilized for cytokine produc-
tion was obtained from an L. (V.) braziliensis strain
(MHOM/BR/75/2903).Thepromastigoteswereresuspended
in phosphate-buﬀered saline (PBS) pH 7.2, at a concentra-
tion of 1 × 108 parasites per mL, and soluble antigens were
preparedthroughsevencyclesoffreezing(−70◦C)andthaw-
ing(37◦C)theparasitesuspension.Thismaterialwasassayed
for protein content, aliquoted, and stored at −70◦C until
used.
CultureofPBMC
PBMCs were puriﬁed by centrifugation (400g, 20◦C,
45minute) over a mixture of Ficoll Hypaque at a den-
sity of 1.077 (Sigma, St. Louis, Mo, USA). After washings
with serum free medium, the cells were resuspended at the
desired concentration in RPMI medium containing 10%
heat-inactivated human AB serum (Sigma), 100IU of peni-
cillin per mL, and 100μg of streptomycin per mL (complete
medium). Fresh PBMCs were cultured in duplicate in 24
well plates at a ﬁnal concentration of 1.25 × 106cells/mL in
2mLcompletemediumfor3days(37◦C,5%CO2),intheab-
sence or presence of ALb, at a ﬁnal protein concentration of
15μg/mL.
Cytokineassays
Aliquots of cell-free supernatants from ALb in vitro-
stimulated PBMC cultures were assayed for TNF-α,I F N - γ,
and IL-12 by means of solid phase sandwich enzyme linked
immunosorbent assays (ELISAs) (BioSource Europe, Bel-
gium). All samples were tested in duplicate and cytokine
concentrations were determined by comparison to standard
curves. The sensitivity of each assay was as follows: TNF-α,
3pg/mL; IFN-γ, 0.03IU/mL; and IL-12, 1.5pg/mL.
Statisticalanalysis
Statistical analysis was performed by the Wilcoxon nonpara-
metric test using the Systat software, version 10.2 (Systat
Software Inc., Richmond, Calif, USA). The level of signiﬁ-
cance was set at P<. 05.
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Figure 1: TNF-α production in cell-free supernatants of CL and
MCL patients’ PBMCs measured by ELISA upon ALb stimulation.
3. RESULTS AND DISCUSSION
The course of MCL has been associated with an unmod-
ulated high production of the proinﬂammatory cytokines
IFN-γ and TNF-α [12]. Considering the high activity of amB
in the treatment of MCL, we decided to compare speciﬁc cy-
tokine production between PBMC from CL and MCL pa-
tients, through an in vitro cell culture approach with ALb,
that would recreate the status of patients’ immune response.
CytokineproductionbyPBMCsfromCLandMCLpatients
TheresponseofPBMCinducedbyALbstimulationwaseval-
u a t e di nt e r m so fT N F - α,I F N - γ, and IL-12 production, at 3
days of culture. While a 72-hour culture period has proven
suﬃcienttostimulateproductionofTNF-αandIFN-γ inpa-
tients’ PBMCs stimulated with leishmanial antigens [12], IL-
12 production is speciﬁcally stimulated as early as 24 hours
of PBMC culture from MCL patients [13].
Whatever the patient group, TNF-α,I F N - γ, and IL-12
were released at similar background levels. Therefore, in this
study, the levels of cytokine released in unstimulated PBMC
cultures did not reﬂect an activated state from contact in
vivo with parasite antigens. Figure 1 reveals a nonsigniﬁ-
cant slight increase in the production of TNF-α in MCL
(1104 ± 732pg/mL), comparing with CL (760 ± 307pg/mL)
patients (P = .1).
The reduced liberation of TNF-α in the supernatants of
MCLpatientsissurprisingconsideringthatamBhasbeenas-
sociated with its production [14] but it also reﬂects the ben-
eﬁcial eﬀect of this drug in MCL as it has been reported that
refractory mucosal leishmaniasis can be successfully treated
through a combination of pentavalent antimony plus pen-
toxifylline, an inhibitor of TNF-α production [15]. Alterna-
tively to the activation of macrophage microbicidal capacity
through the induction of proinﬂammatory cytokines, amB
can also exert its eﬀect intracellularly. Intracellular accumu-
lation of the drug in monocytes augmented the capacity of
the cells to kill ingested Candida albicans [16]. However,Washington R. Cuna et al. 3
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Figure 2: IFN-γ production in cell-free supernatants of CL and
MCL patients’ PBMCs measured by ELISA upon ALb stimulation.
whetherthismechanismofactionisinfactoperatinginMCL
treatment remains to be conﬁrmed.
Contrary to the production of TNF-α,s a m p l e sf r o m
MCL patients had the capacity to signiﬁcantly augment syn-
thesis of IFN-γ with regard patients with CL (17.1±11.5v e r -
sus 4.2 ± 3.2IU/m) [P<. 05] (Figure 2). Furthermore, the
observation of background levels of IL-4 despite stimulation
with ALb (not shown) evokes a TH1-type immune response.
Additionally, and in direct correlation to the increased
production of IFN-γ, there was a much higher concentration
of IL-12 when comparing MCL (175.7 ± 164.8pg/mL)and
CL (26.8 ± 28.2pg/mL) patient cytokine responses (P<. 05)
(Figure 3).FuturestudiesinvitrowithamBwillseektoverify
the cellular source of IL-12 considering that, in human, pe-
ripheral blood monocyte/macrophages are the main produc-
ers of IL-12 [17] .Ap r e v i o u ss t u d y[ 18] reporting suppres-
sion of IL-12 production by murine macrophages infected
with L. mexicana amastigotes on interaction with TH1c e l l s
is of particular interest in the context of this study as it adds
incentive to unveil through the present experimental system
(ALb stimulation) the intracellular signals, likely set in mo-
tion by amB treatment, to increase production of IL-12, one
of the two cytokines most clearly needed for protection in
leishmaniasis.
In general, the present results are reminiscent of a pre-
vious investigation on the use of a recombinant leishma-
nial antigen from Leishmania braziliensis [13]. Apart from
the production of IL-2, this antigen elicited also the pro-
duction of IFN-γ dependent on IL-12, from PBMCs of pa-
tients with mucosal and cutaneous leishmaniasis. By analogy
to our observations, it could be postulated that amB treat-
ment would favor, preferentially, processing of antigens in-
ducing TH1-type immune responses, whereby stimulation of
antigen-presenting cells by IFN-γ leads to IL-12 production,
potentiating in this manner, a positive feedback loop. Even
though amB killing of Leishmania parasites does not require
ah o s ti m m u n er e s p o n s e[ 19], we reason that similar target-
ingoftheTH1-cellmechanismmightincreaseitseﬃcacyand
permit lower doses to be used with compatible activities.
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Figure 3: IL-12 production in cell-free supernatants of CL and
MCL patients’ PBMCs measured by ELISA upon ALb stimulation.
An important aspect to consider in the present study is
thatcytokinesarebeingcomparedintwopatientsgroupsdif-
fering by two parameters, MCL versus CL and treated versus
untreated patients. Hence, there would be the possibility that
theincreaseinIFN-γ andIL-12relatestothediﬀerentclinical
forms rather than to amB treatment. However, it is interest-
ing to note that samples from three MCL patients, not un-
der treatment and excluded from this study, had the capac-
i t yt op r o d u c el o w e rl e v e l so fI F N - γ compared with treated
patients, and this production was not associated with an in-
creased release of IL-12.
Therefore, manipulation of the host’s immune response
in favor of the TH1-cell-associated mechanism may provide
the opportunity to use amB-sparing regimens with lower
doses of drug, fewer injections, and/or a shorter treatment
duration, avoiding toxicity associated with the cumulative
dose. Future studies will seek to improve understanding on
the mechanisms of action of amB at the cellular level, partic-
ularly those associated with increased IL-12 production.
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